TAD Pharma

What TAD Pharma does

TAD Pharma GmbH is a German private limited company headquartered in Cuxhaven, Germany, and a wholly-owned subsidiary of Krka d. d., Novo mesto (Slovenia), one of Europe's leading generic pharmaceutical manufacturers. Operating as the German commercial vehicle of the Krka Group, TAD markets and distributes a portfolio covering eight therapeutic areas: cardiovascular disease (accounting for roughly 59% of Krka's tablet/capsule production), central nervous system, diabetes, oncology, pain management, gastrointestinal, cold/cough, and veterinary antiparasitics. The group's pipeline includes more than 170 products in development and 1,100+ proprietary brands, with 100+ million patients taking Krka-sourced medications daily and products sold in more than 70 countries.

The group's competitive position is built on a vertically integrated operating model that spans in-house API development and production (e.g., Valsartan, Perindopril, Atorvastatin, Esomeprazol) through 16+ billion annual tablets/capsules at facilities across Slovenia, Germany, Russia, Poland, and Croatia. Proprietary drug delivery technologies – osmotic pump systems, double-layer tablets that combine incompatible actives in a single dose, and cellulose-polymer extended-release matrices – are protected by 270+ patents in Europe and Asia and underpin a differentiated generics offering. Quality infrastructure is anchored by GMP, GDP, GLP, HACCP, and ISO 9001/14001/27001/45001 certifications, with a Wholesale Distribution Authorization valid through April 2026.

Revenue is generated through three channels: prescription generics sold to healthcare providers and wholesalers, OTC products (e.g., Septolete, Gingonin) sold through retail pharmacies, and veterinary antiparasitics sold via veterinarians and pet retailers. The commercial model blends a several-thousand-strong medical-representative field force with the TAD4YOU digital platform for healthcare professionals and direct-to-consumer OTC marketing. At the parent level, FY2024 revenue was €1,909.5M (+6% YoY) with €353.4M net profit (+13% YoY) and a 27.1% EBITDA margin; 94% of revenue is generated outside Slovenia.

Name

TAD Pharma

Legal name

TAD Pharma GmbH

Website

https://tad.de

Company type

Private

Founded year

1954

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

TAD Pharma GmbH is a Cuxhaven-based German subsidiary of Slovenia's Krka Group that develops, manufactures, and distributes generic prescription, OTC, and veterinary pharmaceuticals across cardiovascular, CNS, diabetes, oncology, pain, gastrointestinal, and respiratory therapeutic areas for patients, pharmacies, and veterinarians in 70+ countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Generic & Private-Label Veterinary Pharmaceuticals (HLAMAEAM)

Keywords

• Generic pharmaceuticals
• Prescription medicines
• Over-the-counter drugs
• Veterinary medicines
• Cardiovascular treatments

Headquarters

HQ city

Cuxhaven

HQ country

Germany

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceuticals (Rx): Sale of prescription generic pharmaceutical products across therapeutic areas including cardiovascular, CNS, diabetes, oncology, pain, and gastrointestinal. Revenue from contracts with customers for products and services.
2. Over-the-Counter (OTC) Products: Sale of non-prescription pharmaceutical products including cold remedies, pain relievers, and other OTC medications directly to consumers and through pharmacies.
3. Veterinary Pharmaceuticals: Antiparasitic products for animals including pipettes and flavored tablets for pets, sold through veterinarians and pet stores.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

TAD Pharma manufactures and distributes generic prescription pharmaceuticals, over-the-counter (OTC) products, and veterinary medicines across eight therapeutic areas: cardiovascular, gastrointestinal, central nervous system, pain, oncology, diabetes, cold/cough, and veterinary antiparasitics. The company operates a vertically integrated model spanning API development, finished product manufacturing, and global distribution, producing more than 16 billion tablets and capsules annually across 1,100+ proprietary brands.

Product overview

TAD Pharma, a member of the Krka Group, operates as a generic pharmaceutical company offering prescription medicines, over-the-counter (OTC) products, and veterinary medicines. The core product portfolio spans eight therapeutic areas: cardiovascular diseases (59% of production), gastrointestinal disorders, central nervous system conditions, pain management, oncology, cold and cough, diabetes, and veterinary antiparasitics. Key branded OTC products include Septolete (throat care) and Gingonin. The company specializes in advanced pharmaceutical formulations including double-layer tablets, extended-release tablets, and osmotic pump technology. Products are manufactured in various forms: tablets, capsules, powders, granules, syrups, solutions, injections, and infusions. TAD Pharma markets over 1,100 proprietary brands and produces more than 16 billion tablets and capsules annually across its global production network.

Differentiator

Problem solved

Functional benefit

Products and services

• Septolete Over-the-counter medication for the treatment of throat infections and sore throats. Septolete is one of the top five medications for treating sore throats in markets where it is available. Targeted at consumers seeking OTC throat care products.
• Gingonin Over-the-counter herbal/phytopharmaceutical product. Brand websites are maintained in German markets. Targeted at consumers seeking herbal health products.
• Antiparasitic Veterinary Medicines Antiparasitic medications for pets including pipettes and flavored tablets to protect animals from external and internal parasites. Sold through veterinarians and pet stores. Received the "Easy to Give" award from International Cat Care in 2022 for innovative, easy-to-use pipette.
• Cardiovascular Pharmaceuticals Prescription generic medications for treating cardiovascular diseases including hypertension and cholesterol control. Features innovative single-pill combinations with two or more active ingredients. 59% of all Krka tablets and capsules are used for cardiovascular treatments.
• Gastrointestinal Pharmaceuticals Prescription generic proton pump inhibitors (PPIs) for treating gastric acid-related conditions including heartburn and stomach pain. Includes Esomeprazole in pellet capsules for extended release.
• Central Nervous System Pharmaceuticals Prescription medications targeting diseases of the central nervous system including depression, anxiety disorders, panic attacks, schizophrenia, dementia, and Parkinson's disease. Backed by over 55 years of experience in CNS treatments. Includes paliperidone with proprietary osmotic pump technology.
• Pain Management Pharmaceuticals Analgesic medications for treating mild to severe pain and neuropathic pain. Products have been providing effective pain relief for over 40 years. Offered in prescription and OTC forms.
• Cold and Cough Pharmaceuticals OTC medications for treating cold and cough symptoms including sore throat, cough, nasal congestion, and fever. Includes Herbion, a natural cough syrup preferred in Central, Eastern, and Southeast Europe.
• Diabetes Pharmaceuticals Prescription medications for Type 2 diabetes treatment including Gliclazide extended-release tablets. Features low hypoglycemia risk and focuses on maintaining pancreatic insulin secretion.
• Oncology Pharmaceuticals Prescription cancer treatment medications covering breast cancer, colorectal cancer, gastric cancer, prostate cancer, pancreatic cancer, leukemia, lymphoma, and multiple myeloma. Includes pomalidomide and lenalidomide with peel-off blisters and calendar packaging, and imatinib (covered by a granted European patent).

Quantifiable outcome

• More than 100 million patients worldwide treated daily with Krka medications
• +4 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Approved Suppliers NetworkcoreOthersSystem of approved suppliers established to ensure timely provision of high-quality raw materials including APIs, excipients, and packaging materials. 600 business partners from 48 countries integrated into supply chain.

Scale indicators17 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with an extensive small-molecule generics portfolio and a strong European footprint. It competes with TAD/Krka across most therapeutic areas and serves similar pharmacy and wholesaler channels, with comparable distribution scale across multiple European countries.
• Stada Arzneimittel AG: Stada is a German-headquartered generic and specialty pharmaceutical company operating across Europe with vertically integrated manufacturing and a broad retail generics portfolio. It is the closest direct competitor to TAD/Krka in the German-speaking and broader European generics market, competing head-to-head in cardiovascular, CNS, and OTC segments.
• Sandoz (Novartis): Sandoz is one of the world's largest generic and biosimilar pharmaceutical companies, offering small-molecule generics across cardiovascular, CNS, pain, and gastrointestinal therapeutic areas. It directly competes with TAD/Krka in European tenders, has comparable vertically integrated capabilities, and matches TAD's broad portfolio strategy.
• Dr. Reddy's Laboratories: Dr. Reddy's is a global generics manufacturer with significant European operations and a portfolio overlapping TAD/Krka's therapeutic areas. It competes in Western and Central European tenders, has comparable API/finished-dose capabilities, and pursues similar proprietary formulation differentiation strategies.
• Aurobindo Pharma: Aurobindo is a large Indian-headquartered generic pharmaceutical manufacturer with vertically integrated API-to-finished-dose operations and a broad European generics footprint. It competes with TAD/Krka in European tenders, particularly in cardiovascular and CNS, leveraging comparable cost-driven vertically integrated economics.
• Viatris (Mylan + Upjohn): Viatris is a global generics and specialty pharmaceutical company formed from the Mylan-Upjohn combination, with a particularly strong cardiovascular and CNS generics portfolio. It competes directly with TAD/Krka in European tenders and OTC channels and operates at a similar vertical-integration model.
• Zentiva Group: Zentiva is a European-focused generic pharmaceutical company headquartered in Prague with strong Central and Eastern European market presence. It competes head-to-head with TAD/Krka in CEE tenders and offers overlapping cardiovascular and OTC portfolios with a comparable regional go-to-market approach.

Emerging players

• Alvotech: Alvotech is a biosimilar-focused biopharmaceutical company with development and manufacturing operations partly in Europe. While focused on biosimilars rather than small-molecule generics, it overlaps with TAD/Krka in the broader strategy of moving up the value chain through proprietary formulation technologies and serves similar payer and tender markets.

Regional players

• Polpharma Biologics: Polpharma is the largest Polish pharmaceutical manufacturer with a strong generics portfolio across cardiovascular and OTC categories. It is a regional peer in Central/Eastern Europe with overlapping therapeutic coverage, comparable manufacturing footprint, and similar channel relationships with regional wholesalers and pharmacy chains.

Broad incumbents

• Merck KGaA (Healthcare / Generics): Merck KGaA is a German-headquartered broad life sciences incumbent that participates in the European pharmaceutical market across multiple categories. While not a pure-play generics competitor, it competes in adjacent pharmaceutical segments, serves overlapping healthcare professional channels, and has comparable German regulatory and manufacturing infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights1 record

Customer concentration

• YouTubeyoutube.com/watch?v=KeEYOMg_KSQ
• Facebookfacebook.com/178282179424282

Compliance10 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TAD Pharma